Aeolus' AEOL 10150 Subject of $4.3 Million US Government Award for Protection Against Nerve Agents; Data Shows Drug Significantly Improves Survival in Animals Following Exposure to Pilocarpine, a Nerve Agent Surrogate for Soman and Sarin Gas
September 11, 2013 12:20 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Sep 11, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
National Institutes of Health - National Institute of Neurological...
Aeolus Announces Third Quarter Fiscal Year 2013 Financial Results
August 14, 2013 16:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 14, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus' AEOL 10150 Significantly Improves Survival From Nitrogen Mustard Exposure to Skin in Animals
July 02, 2013 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jul 2, 2013) - Aeolus Pharmaceuticals (OTCQB: AOLS)
Data presented at 6th Annual NIH CounterACT Network Research Symposium
...
Aeolus' AEOL 10150 Significantly Improves Survival in Animals Exposed to Mustard Gas
June 26, 2013 14:02 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jun 26, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Data presented at 7th Annual NIH CounterACT Network Research...
Aeolus Strengthens Board of Directors With Oncology, Government Contracting and Financial Industry Veterans
May 17, 2013 14:19 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 17, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel...
Aeolus Pharmaceuticals Announces Second Quarter Fiscal Year 2013 Financial Results
May 15, 2013 14:38 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 15, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel...
Aeolus Provides Investor Update on Passage of Pandemic All-Hazards Preparedness Act of 2013
March 14, 2013 08:31 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Mar 14, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Bill Signed into Law by President Obama
Passed Senate...
Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2013 Financial Results
February 19, 2013 18:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 19, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Beginning Third Year of $118.4 Million BARDA Advance Research and...
Aeolus Pharmaceuticals Announces $3.2 Million Private Placement Financing
February 19, 2013 17:46 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 19, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel...
Aeolus Pharmaceuticals Announces Fiscal Year 2012 Results
January 02, 2013 10:59 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Jan 2, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel...